The human lymphoma cell line Jurkat (ACC282) and the human lymphoblast cell line TK6 (ATCC CRL-8015) were used. The cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; PAN-Biotech, Aidenbach, Germany) or Roswell Park Memorial Institute (RPMI) 1640 medium (PAN-Biotech, Aidenbach, Germany), each containing 10% fetal bovine serum (Sigma-Aldrich-Chemie, Taufkirchen, Germany), 1% glutamine (PAN-Biotech), and 1% penicillin/streptomycin (PAN-Biotech, Aidenbach, Germany) at 37 °C and 5% CO2. Before the treatment, the cells were seeded at 5 × 104 in 100 µL DMEM into 96-well round bottom plates (Thermo Fisher Scientific, Dreieich, Germany). For a different set of experiments, 2.5 × 105 cells in 500 µL of RPMI medium were seeded into flat-bottom 24-well plates (Eppendorf, Hamburg, Germany).
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.